At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 70 enrolled
Drug / intervention
Herpes Zoster Vaccine GSK1437173Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine 1437173A and Assessment of Re-vaccination With 2 Additional Doses, in Healthy Subjects Aged 60 Years of Age and Older
In Brief
A Phase 3 clinical trial evaluating Herpes Zoster Vaccine GSK1437173A for Herpes Zoster. Completed, enrolled 70 participants across 7 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course. This study will also assess immune responses after re-vaccination with 2 additional doses of the HZ/su administered at ten years after first dose of initial vaccination course from study Zoster-003 (NCT00434577).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesCzechia, Germany, Sweden
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedApr 2016
Primary CompletionAug 2017
Study CompletionOct 2018
TodayJul 2026
First PostedApr 13, 2016
Enrollment StartApr 11, 2016
Primary CompletionAug 28, 2017
Study CompletionOct 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.2 years ago
Interventions
Herpes Zoster Vaccine GSK1437173Abiological
Intramuscular injection